Researchers discover a cause of neuron excitability in ALS, suggesting a new potential treatment

by Les Turner ALS Foundation

edited by Sadie Harley, reviewed by Robert Egan

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

proofread

The GIST Add as preferred source

Digging deep into the molecular mechanisms behind ALS, researchers at the Les Turner ALS Center at Northwestern Medicine have discovered why nerve cells overfire in the disease. Not only that—they have also designed a new drug to stop this overfiring, which could potentially slow or stop the disease from progressing.

"If we figure out the cause and we get the mechanism right, we can actually treat the disease," said Evangelos Kiskinis, associate professor of neurology and neuroscience at Northwestern University's Feinberg School of Medicine, who led the research.

Using patient nervous tissue and lab-grown human neurons—which he develops from stem cells—Kiskinis has focused his research on the protein TDP-43.

In ALS patients, this protein moves from its normal cellular location and disrupts cellular function. "We believe that understanding the functional process of TDP-43 pathology is the key to understanding what happens in sporadic ALS," he said. Sporadic ALS accounts for the vast majority of cases of the disease.

How TDP-43 disrupts firing

When Kiskinis and his team manipulated the expression of TDP-43, they found that it caused several defects associated with a neuron's ability to fire and communicate.

They discovered that TDP-43 affects an ion channel that acts as a brake for brain cells—when there is too much firing, the ion channel regulates it and slows it down. But many ALS patients show hyperexcitability in their brain cells. Kiskinis believes that TDP-43 causes this hyperexcitability by affecting the ion channel.

Not only has the research uncovered the explanation for this hyperexcitability, it has also led Kiskinis and his team to design a drug that could stop it.

The drug is a new type of therapeutic called an antisense oligonucleotide. A similar drug is used to treat spinal muscular atrophy and has been shown to substantially slow neurodegeneration. These types of drugs work by identifying and binding to a specific, defective RNA molecule in cells, then working to correct it.

"We discovered that the RNA, which makes this ion channel break, is defective because it is regulated by TDP-43," Kiskinis said. "So this type of therapy makes perfect sense to treat it."

From lab finding to therapy

The team is currently planning preclinical studies, including safety studies in animal models, and hopes to advance it to clinical trials in humans soon.

"We hope to establish a platform that would allow us to test this molecule on patients at Northwestern," he said.

Robert Kalb, director of the Les Turner ALS Center at Northwestern Medicine, said this far-reaching and comprehensive study links several enigmatic aspects of motor neuron disease: the electrical excitability of neurons, TDP-43 pathology and the rate of ALS progression in patients.

"Remarkably, preventing the generation of the abnormal ion channel with antisense oligonucleotides blunts this pathology," he said. "Together, this mechanistic work suggests a novel therapeutic avenue for future interrogations."

Broader hopes for sporadic ALS

Research like this is possible because Kiskinis and his team are building innovative cellular models by pooling together stem cell lines derived from multiple ALS patients. The eventual goal is to gather hundreds of stem cells from people living with sporadic ALS to find even more opportunities for treatments to stop the disease from progressing.

Current ALS drugs are showing positive results, but they are designed to treat only the genetic version of the disease. Kiskinis hopes that this new therapy could finally help push the field toward finding ways to treat sporadic ALS.

"Within this decade, we're going to see transformative changes in the way we treat ALS patients," he said. "I remain incredibly hopeful."

Key medical concepts

Amyotrophic Lateral SclerosisAntisense TherapyTAR DNA binding proteinSpinal Muscular Atrophy

Clinical categories

NeurologyClinical pharmacology Provided by Les Turner ALS Foundation Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Researchers discover a cause of neuron excitability in ALS, suggesting a new potential treatment (2026, June 28) retrieved 29 June 2026 from https://medicalxpress.com/news/2026-06-neuron-als-potential-treatment.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.